Corbus Q1 net loss $23M, cash $138.2M; FDA alignment for CRB-701 registration path

Corbus Pharmaceuticals Holdings, Inc.

• Net loss of $23.0M ($1.23 diluted LPS) vs $17.0M loss ($1.39 LPS) in Q1 2025.
• Cash and investments $138.2M as of March 31, 2026, expected to fund operations into 2028.
• Reached broad FDA alignment on registration path for CRB-701 in 2L HNSCC and cervical cancer; registrational study start expected summer 2026.
• Updated CRB-701 data to be presented at ASCO 2026; CANYON-1 obesity study (n=240) fully enrolled, topline data summer 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.